Date:	2023/02/	05	
Your Nan	ne: Jinhua	a Chen	
Manuscri	ipt Title: Tumor ne	ecrosis factor-related IncR	NAs predict prognosis and immunotherapy response for
	with lung adenocarcing		
-	ipt number (if known):		
In the int	erest of transparency,	we ask you to disclose all	relationships/activities/interests listed below that are
		_	ins any relation with for-profit or not-for-profit third
	-	-	f the manuscript. Disclosure represents a commitment
			If you are in doubt about whether to list a
•	•	is preferable that you do	•
The follow	wing questions apply t	o the author's relationship	os/activities/interests as they relate to the current
<u>manuscri</u>	pt only.		
	•		defined broadly. For example, if your manuscript pertains
to the ep	idemiology of hyperte	nsion, you should declare	all relationships with manufacturers of antihypertensive
medication	on, even if that medica	tion is not mentioned in t	he manuscript.
	•	-	d in this manuscript without time limit. For all other items,
the time	frame for disclosure is	the past 36 months.	
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	al planning of the work
1 All su	upport for the present	XNone	
	uscript (e.g., funding,		
-	ision of study materials,		
	ical writing, article		
	essing charges, etc.)		
No t	ime limit for this item.		

Time frame: past 36 months

X__None

X_None

X__None

Grants or contracts from

in item #1 above).

Consulting fees

Royalties or licenses

3

4

any entity (if not indicated

		1	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
	_		
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		
ы.		COLUMN CO	· Harantana Karantana

Please place an "X" next to the following statement to indicate your agreement:

Date:	2023/02/05	
Your Name:	Xuan Wu	
Manuscript Title:	Tumor necrosis fa	actor-related IncRNAs predict prognosis and immunotherapy response for
patients with lung	adenocarcinoma	
Manuscript numbe	r (if known):	
	•	you to disclose all relationships/activities/interests listed below that are pt. "Related" means any relation with for-profit or not-for-profit third

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)			
	Time frame: Since the initial planning of the work					
1	All support for the present	XNone				
	manuscript (e.g., funding,					
	provision of study materials,					
	medical writing, article					
	processing charges, etc.) No time limit for this item.					
	No time limit for this item.					
		Time frame: past	36 months			
2	Grants or contracts from	XNone				
	any entity (if not indicated					
	in item #1 above).					
3	Royalties or licenses	XNone				
4	Consulting fees	XNone				

		1	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
	_		
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		
ы.		COLUMN CO	· Harantana Karantana

Please place an "X" next to the following statement to indicate your agreement:

Date:	2023/02/05	
Your Name:	Ziming Wang_	
patients with lung	adenocarcinoma	actor-related IncRNAs predict prognosis and immunotherapy response for
In the interest of t	ransparency, we ask	you to disclose all relationships/activities/interests listed below that a

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

		1	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
	_		
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		
ы.		COLUMN CO	· Harantana Karantana

Please place an "X" next to the following statement to indicate your agreement:

Date:	2023/02/05	
Your Name:	Ziyang Liu	
	_ Tumor necrosis factor-related IncRNAs predict prognosis and immunotherapy response enocarcinoma	for
Manuscript number	if known):	-
In the interest of tra	sparency, we ask you to disclose all relationships/activities/interests listed below that a	re
parties whose inter	t of your manuscript. "Related" means any relation with for-profit or not-for-profit third sts may be affected by the content of the manuscript. Disclosure represents a commitment does not necessarily indicate a bias. If you are in doubt about whether to list a	

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

		1	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
	_		
12		XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		
ы.		COLUMN CO	· Harantana Karantana

None		

Please place an "X" next to the following statement to indicate your agreement:

patients with lung adenocarcinoma Manuscript number (if known): In the interest of transparency, we ask you to disclerelated to the content of your manuscript. "Related parties whose interests may be affected by the conto transparency and does not necessarily indicate a relationship/activity/interest, it is preferable that y The following questions apply to the author's relational manuscript only. The author's relationships/activities/interests shout to the epidemiology of hypertension, you should demedication, even if that medication is not mentioned in item #1 below, report all support for the work results.	ose all relationships/activities/interests listed below that are liminated means any relation with for-profit or not-for-profit third tent of the manuscript. Disclosure represents a commitment bias. If you are in doubt about whether to list a
Manuscript Title: Tumor necrosis factor-related patients with lung adenocarcinoma Manuscript number (if known): In the interest of transparency, we ask you to disclerelated to the content of your manuscript. "Related parties whose interests may be affected by the conto transparency and does not necessarily indicate a relationship/activity/interest, it is preferable that y The following questions apply to the author's relational manuscript only. The author's relationships/activities/interests shout to the epidemiology of hypertension, you should demedication, even if that medication is not mentioned in item #1 below, report all support for the work results.	d IncRNAs predict prognosis and immunotherapy response for ose all relationships/activities/interests listed below that are means any relation with for-profit or not-for-profit third tent of the manuscript. Disclosure represents a commitment bias. If you are in doubt about whether to list a ou do so.
In the interest of transparency, we ask you to disclerelated to the content of your manuscript. "Related parties whose interests may be affected by the conto transparency and does not necessarily indicate a relationship/activity/interest, it is preferable that y The following questions apply to the author's relatimanuscript only. The author's relationships/activities/interests shout to the epidemiology of hypertension, you should demedication, even if that medication is not mentioned. In item #1 below, report all support for the work residues.	ose all relationships/activities/interests listed below that are I" means any relation with for-profit or not-for-profit third tent of the manuscript. Disclosure represents a commitment bias. If you are in doubt about whether to list a ou do so.
In the interest of transparency, we ask you to disclerelated to the content of your manuscript. "Related parties whose interests may be affected by the conto transparency and does not necessarily indicate a relationship/activity/interest, it is preferable that y The following questions apply to the author's relational manuscript only. The author's relationships/activities/interests shout to the epidemiology of hypertension, you should demedication, even if that medication is not mentioned. In item #1 below, report all support for the work respectively.	ose all relationships/activities/interests listed below that are I" means any relation with for-profit or not-for-profit third tent of the manuscript. Disclosure represents a commitment bias. If you are in doubt about whether to list a ou do so.
related to the content of your manuscript. "Related parties whose interests may be affected by the conto transparency and does not necessarily indicate a relationship/activity/interest, it is preferable that y The following questions apply to the author's relatimanuscript only. The author's relationships/activities/interests shout to the epidemiology of hypertension, you should demedication, even if that medication is not mentioned.	" means any relation with for-profit or not-for-profit third tent of the manuscript. Disclosure represents a commitment bias. If you are in doubt about whether to list a ou do so.
manuscript only. The author's relationships/activities/interests shou to the epidemiology of hypertension, you should de medication, even if that medication is not mentioned in item #1 below, report all support for the work re	onships/activities/interests as they relate to the <u>current</u>
to the epidemiology of hypertension, you should demedication, even if that medication is not mentioned in item #1 below, report all support for the work re	
• • • • • • • • • • • • • • • • • • • •	Id be <u>defined broadly</u> . For example, if your manuscript pertains eclare all relationships with manufacturers of antihypertensive ed in the manuscript.
·	ported in this manuscript without time limit. For all other items,
Name all entities wi	th Specifications/Comments
whom you have this relationship or indic none (add rows as needed)	(e.g., if payments were made to you or to your

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

		•	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
	-		
8	Patents planned, issued or pending	XNone	
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	X None	
13	financial interests		
	ilitaticiai litterests		
Dloa	use summarize the above co	nflict of interest in the	following boy:

None		

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this

form.

Date: Your Name:	2023/02/05 Wenping Song	 				
patients with lun	Tumor necrosis fa g adenocarcinoma per (if known):	 •	edict progn	osis and im	ımunotherapy ı	response for
•			_	_		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

		1	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
	_		
12		XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		
ы.		COLUMN CO	· Harantana Karantana

None		

Please place an "X" next to the following statement to indicate your agreement:

Date:	2023/02/05	
Your Name:		g
•	e: Tumor necrosis fa ng adenocarcinoma	ctor-related IncRNAs predict prognosis and immunotherapy response for
-		
	• • •	ou to disclose all relationships/activities/interests listed below that are ot. "Related" means any relation with for-profit or not-for-profit third

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
	Time frame: Since the initial planning of the work								
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	XNone							
	processing charges, etc.) No time limit for this item.								
		Time frame: past	36 months						
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone							
3	Royalties or licenses	X_None							
4	Consulting fees	XNone							

		1	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		
DI		CITAL COLLEGE COLLEGE	and the first

None		

Please place an "X" next to the following statement to indicate your agreement:

 $\underline{\mathbf{X}}$ I certify that I have answered every question and have not altered the wording of any of the questions on this

form.